BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jan 07, 2008
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 1/4 cls
Amgen (NASDAQ:AMGN) Lazard Joel Sendek Upgrade Hold (from sell) -5% $44.80
Sendek sees the stock as fairly valued at $46, a five-year low. Still, he expects Amgen to report disappointing 4Q07 earnings and FDA's Oncologic Drugs Advisory Committee (ODAC) to place further restrictions on erythropoiesis-stimulating agents (ESAs) at its meeting in 1Q08, which could lead to more share price deterioration. Amgen markets two ESAs: Aranesp darbepoetin alfa for cancer and renal indications, and Epogen epoetin alfa for chronic renal failure.
CombinatoRx (NASDAQ:CRXX) Piper Jaffray Edward Tenthoff Upgrade Buy (from neutral) -1% $4.35
Tenthoff raised his target to $7 from $6. He thinks CRx-102 is a potential blockbuster and anticipates a partnership if data from two Phase IIb trials of the selective steroid amplifier, which contains dipyridamole and prednisolone, are positive. Data from the COMET-1 trial to treat knee osteoarthritis (OA) and MARS-1 trial to treat rheumatoid arthritis (RA) are expected in...

Read the full 988 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >